Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Insider Eric A. Hughes Sells 52,742 Shares

Key Points

• Teva Pharmaceutical Industries insider Eric A. Hughes sold 52,742 shares at an average price of $15.16, totaling approximately $799,568.72.
• The company's stock experienced a slight increase of 0.2%, reaching $15.72, while the stock has a 1-year range between $12.47 and $22.80.
• Several analysts have upgraded Teva's rating, with a consensus target price of $24.71 and a majority indicating a "buy" stance on the stock.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) insider Eric A. Hughes sold 52,742 shares of the business's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Teva Pharmaceutical Industries Stock Up 0.2%

NYSE TEVA traded up $0.03 during mid-day trading on Tuesday, reaching $15.72. 10,288,711 shares of the company's stock traded hands, compared to its average volume of 12,245,117. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $22.80. The company has a fifty day simple moving average of $16.86 and a 200-day simple moving average of $16.56. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45. The company has a market cap of $18.03 billion, a price-to-earnings ratio of -98.25, a P/E/G ratio of 0.91 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%. The company had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. During the same quarter last year, the business posted $0.61 EPS. Teva Pharmaceutical Industries's quarterly revenue was up .3% compared to the same quarter last year. As a group, equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Analyst Ratings Changes

Several analysts have weighed in on the company. Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price objective for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Truist Financial initiated coverage on Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective on the stock. The Goldman Sachs Group initiated coverage on Teva Pharmaceutical Industries in a research report on Friday, June 6th. They issued a "buy" rating and a $24.00 price objective on the stock. Finally, Bank of America upped their price objective on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Teva Pharmaceutical Industries has an average rating of "Buy" and a consensus target price of $24.71.

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds have recently made changes to their positions in TEVA. FMR LLC increased its position in shares of Teva Pharmaceutical Industries by 30.7% during the 4th quarter. FMR LLC now owns 81,983,231 shares of the company's stock valued at $1,806,910,000 after purchasing an additional 19,242,468 shares during the period. Ion Asset Management Ltd. boosted its position in shares of Teva Pharmaceutical Industries by 6.5% in the first quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company's stock worth $599,945,000 after buying an additional 2,383,500 shares during the period. Phoenix Financial Ltd. boosted its position in shares of Teva Pharmaceutical Industries by 31.7% in the second quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company's stock worth $632,882,000 after buying an additional 9,094,372 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its position in Teva Pharmaceutical Industries by 51.4% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company's stock valued at $559,622,000 after purchasing an additional 11,334,780 shares during the last quarter. Finally, Menora Mivtachim Holdings LTD. boosted its position in Teva Pharmaceutical Industries by 2.8% during the first quarter. Menora Mivtachim Holdings LTD. now owns 29,189,316 shares of the company's stock valued at $448,640,000 after purchasing an additional 808,074 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.